-
Posted by
Two Blokes Jun 15 -
Filed in
Stock
-
9 views
AbbVie is undervalued, trading at under 16x 2025 earnings, despite robust EPS growth, a strong pipeline, and successful Humira diversification. Skyrizi and Rinvoq are driving immunology revenue, expected to surpass $15 billion by 2027, with neuroscience and oncology portfolios also showing strong growth. AbbVie has delivered 11 consecutive years of dividend increases, with a 7.23% five-year CAGR and a current yield of 3.43%, rewarding shareholders consistently.
